Brief: Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
15/05/2024 13:36
May 15 (Reuters) - Veru Inc VERU.O :
* VERU ANNOUNCES STEVEN B. HEYMSFIELD M.D. AS THE PRINCIPAL
INVESTIGATOR FOR ITS ENOBOSARM PHASE 2B CLINICAL TRIAL FOR HIGH
QUALITY WEIGHT LOSS
Source text for Eikon: ID:nGNX7V20fQ
Further company coverage: VERU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veru
See all newsUS STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Oppenheimer upbeat on Veru, says 'come for the lean mass, stay for the muscle function'
Veru Inc. reports results for the quarter ended June 30 - Earnings Summary